tldrdailynews.com logo
Tag

Bladder Cancer

All articles tagged with #bladder cancer

New Urine RNA Test Detects 95% of Bladder Cancers and Predicts Treatment Response
health-and-science8 days ago

New Urine RNA Test Detects 95% of Bladder Cancers and Predicts Treatment Response

Researchers at Stanford Medicine and the VA Palo Alto Health Care System developed uRARE-seq, a urine-based liquid biopsy that detects localized bladder cancer with 95% sensitivity and 90% specificity. Unlike DNA-based tests, this method analyzes cell-free RNA to assess tumor activity, distinguishing between low- and high-grade cancers. The test also predicts whether patients will respond to BCG immunotherapy or require chemotherapy, potentially reducing the need for invasive cystoscopies and optimizing treatment allocation.

via Nature|
#bladder-cancer#health-and-science#immunotherapy
Bladder cancer evolution reveals early founders, polyclonal spread and subtype-specific aggressiveness
science24 days ago

Bladder cancer evolution reveals early founders, polyclonal spread and subtype-specific aggressiveness

A multi-omics analysis of lethal metastatic bladder cancer from a rapid-autopsy program shows metastasis-to-metastasis seeding as the dominant spread pattern and polyclonal migration linked to worse survival. Histology-driven differences include early founder alterations in plasmacytoid and neuroendocrine variants, with cisplatin resistance in plasmacytoid tumors associated with Fanconi anaemia pathway activity. Single-nucleus RNA sequencing reveals substantial transcriptional and microenvironmental heterogeneity across subtypes, while post-mortem cfDNA captures the majority of driver alterations, offering a noninvasive readout of tumor identity and aggressiveness to guide therapy.

via Nature|
#bladder-cancer#circulating-cell-free-dna#metastasis
Home urine test could flag majority of bladder cancers, NHS trial finds
health1 month ago

Home urine test could flag majority of bladder cancers, NHS trial finds

An at‑home Galeas urine test, developed by the University of Birmingham and Nonacus, detected 92% of bladder cancer cases in an NHS study of about 1,000 patients across seven hospitals; a negative result offered >99% reassurance that cancer is unlikely. While not a replacement for cystoscopies, the test could help triage patients for urgent checks and reduce invasive testing if larger trials confirm these findings. The test looks for more than 450 DNA mutations across 23 genes and is licensed to Nonacus with funding from Cancer Research UK.

via BBC|
#bladder-cancer#diagnostics#early-detection
ImmunityBio's NAI+BCG Delivers More Durable Complete Responses in BCG-Unresponsive NMIBC at AUA 2026
business4 months ago

ImmunityBio's NAI+BCG Delivers More Durable Complete Responses in BCG-Unresponsive NMIBC at AUA 2026

ImmunityBio presented indirect treatment comparison analyses at AUA 2026 showing nogapendekin alfa inbakicept-pmln (NAI) plus BCG achieving higher and longer-lasting complete responses than nadofaragene firadenovec-vncg in BCG-unresponsive NMIBC with CIS (anytime CR 69.7% vs 53.4%; median CR duration 22.1 vs 9.7 months; cystectomy-free HR 0.40). In comparison with TAR-200, NAI+BCG had a higher 12‑month CR (49.2% vs 45.9%) and substantially fewer treatment-related adverse events (61.7% vs 83.5%) based on MAIC analyses. Results are from unanchored indirect comparisons and should be interpreted with caution, but support IL-15–driven, bladder-sparing immunotherapy potential in NMIBC with CIS. The company also cites ongoing BCG development efforts, including Tokyo strain and recombinant BCG programs.

via ImmunityBio|
#anktiva#aua-2026#bladder-cancer
Colorblindness May Obscure Bladder Cancer Clues and Raise Mortality Risk
health8 months ago

Colorblindness May Obscure Bladder Cancer Clues and Raise Mortality Risk

Stanford Medicine analyzed large electronic health records via the TriNetX platform and found colorblind individuals diagnosed with bladder cancer had a 52% higher risk of death over 20 years compared with color-normal patients, likely due to delayed detection of blood in urine. The effect was not seen for colorectal cancer. The study suggests clinicians consider color vision differences in screening and encourage urine testing when suspicion arises; the researchers note possible undercounting and call for further investigation.

via SciTechDaily|
#bladder-cancer#cancer-survival#color-vision-deficiency
Colorblindness Linked to Higher Bladder Cancer Mortality, Study Finds
health8 months ago

Colorblindness Linked to Higher Bladder Cancer Mortality, Study Finds

A Stanford-led analysis of electronic health records found colorblind individuals diagnosed with bladder cancer had a 52% higher risk of death over 20 years compared with non-colorblind patients, possibly because they don’t notice blood in urine—the key early sign—while no mortality difference was observed for colorectal cancer. The authors stress this is hypothesis-generating and call for further research and awareness about diagnostic cues and potential screening considerations for color vision deficiency.

via Gizmodo|
#bladder-cancer#cancer-mortality#colorblindness
ImmunityBio stock climbs as FDA maps resubmission route for ANKTIVA
markets8 months ago

ImmunityBio stock climbs as FDA maps resubmission route for ANKTIVA

ImmunityBio (IBRX) shares rose about 26% after the FDA outlined a potential resubmission path for ANKTIVA in BCG-unresponsive papillary non-muscle invasive bladder cancer, saying additional information is needed to support a supplemental Biologics License Application but no new clinical trials are required, a development investors view as de-risking the regulatory process and potentially enabling a broader label. Trading volume surged on Nasdaq amid the regulatory update and ongoing volatility around ANKTIVA’s commercialization prospects.

via Nasdaq|
#anktiva#bladder-cancer#fda
biotechnology8 months ago

ImmunityBio Pursues FDA Path to Resubmission for ANKTIVA in Papillary NMIBC

ImmunityBio announced a productive Type B End‑of‑Phase meeting with the FDA regarding its supplemental Biologics License Application for ANKTIVA plus BCG in BCG‑unresponsive papillary NMIBC. The FDA asked for additional information (not new trials) to support a potential resubmission, which ImmunityBio will provide within 30 days. Long‑term QUILT‑3.032 data in 80 patients show about 96% bladder cancer‑specific survival at 36 months and high cystectomy‑free survival (roughly 82–93% at 12–36 months), underscoring a bladder‐sparing, chemo‑free approach. ANKTIVA is already approved for CIS in the US, UK, and Saudi Arabia, with EU conditional status for CIS and ongoing EMA discussions to extend labeling to papillary disease if US approval is achieved.

via Business Wire|
#antkiva#biotechnology#bladder-cancer
KEYTRUDA and Padcev Boost Survival and Response in Cisplatin-Eligible MIBC Patients
healthcare9 months ago

KEYTRUDA and Padcev Boost Survival and Response in Cisplatin-Eligible MIBC Patients

Merck announced positive results from the Phase 3 KEYNOTE-B15 trial showing that combining KEYTRUDA (pembrolizumab) with Padcev (enfortumab vedotin) before and after surgery significantly improves survival and response rates in cisplatin-eligible muscle-invasive bladder cancer patients, with a safety profile consistent with known effects.

via Merck.com|
#bladder-cancer#clinical-trial#healthcare
Innovative Treatment Achieves 82% Success in Bladder Cancer Cure
health11 months ago

Innovative Treatment Achieves 82% Success in Bladder Cancer Cure

A new implant called TAR-200 has shown promising results in a phase 2 trial, eliminating tumors in 82% of high-risk bladder cancer patients resistant to previous treatments, with most tumors disappearing within three months and many patients remaining cancer-free after a year, offering a potentially safer and more effective alternative to traditional therapies.

via ScienceDaily|
#bladder-cancer#cancer-treatment#clinical-trial